TAK1 has not been investigated in the context of MM or bladder cancer; however, it’s downstream target, NFκB, has emerged as one of the most potent drivers of tumorigenesis in MM, with as many as 82% of MM samples expressing signature activation molecules [26], [27]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.